Acupuncture's ability to stimulate endorphin production may partly explain the clinical improvements.
Adding chemotherapy to hormone therapy added 14 months to patients' lives in study.
Patients with longer life expectancy are most at risk of cardiac morbidity, researchers concluded.
Many men with low-risk disease being spared prostatectomy, radiation, and androgen deprivation treatment.
Researchers observed greater incidences of colorectal cancer among patients who underwent bilateral orchiectomy, surgery, and ADT.
Researchers observed increases in components of metabolic syndrome and in the prevalence of full metabolic syndrome among men with prostate cancer treated with ADT.
Findings among men treated for localized prostate cancer.
The combination improved oncologic control better than dose-escalated radiotherapy alone in men with intermediate-risk prostate cancer.
Men with a particular gene mutation affected most, researchers find.
This effect appears to occur mainly in men who experience recurrence when they are younger than 65 and in those with low-risk cancer.
Prostate cancer remained stable for an average 10 extra months in men taking statins, but more trials are needed to confirm benefits, researchers say.
Prolonged androgen deprivation treatment ups risk in older men with prostate cancer, especially those with comorbidities.
Median time to death was shortest in men with metastatic disease at diagnosis.
Physical side effects seen over first 12 months of androgen deprivation therapy (ADT) persisted or worsened over 3 years of follow-up.
Studies suggest that these cholesterol-lowering drugs can improve treatment of genitourinary cancers and prevent contrast-induced nephropathy.
Low serum testosterone levels within the first year of androgen-deprivation therapy (ADT) is associated with improved cause-specific survival.
The researchers found that 12% of the participants experienced treatment decisional regret.
Highest risk during first 6 months of ADT among men who had cardiovascular events before treatment.
Adding short-term androgen deprivation therapy to radiotherapy does not improve overall survival in intermediate-risk prostate cancer.
Researchers observed a significant 36% decreased overall and prostate cancer-specific mortality.
The 5-year risk of overall mortality is decreased by 50% compared with androgen deprivation therapy alone.
Prostate cancer progression was delayed by a median 10 months in statin users.
Small study suggests alternating testosterone levels may make hormonal therapy work longer for prostate cancer patients.
Longer cancer-specific and overall survival seen in older men with locally advanced or high-risk PCa
PSA doubling time of 6 months or less and seminal vesicle invasion were significant predictors of biochemical recurrence.
Androgen-deprivation therapy (ADT) for more than 1 year is associated with a 2.5 times higher odds of fracture in prostate cancer patients.
Testosterone replacement therapy (TRT) may lower hemoglobin levels and improve lipid profile in diabetic men with androgen deficiency.
But overall risk of heart-related death risk from prostate cancer treatment is small, researchers say.
Starting docetaxel with androgen deprivation therapy prolonged median overall survival by more than 13 months versus ADT alone.
Immediate ADT found to offer little or no survival advantage to prostate cancer who experience biochemical recurrence.
- Transperineal Prostate Biopsy Better for PCa Risk Statification
- Androgen Deprivation for Localized Prostate Cancer Ups Cardiac Risks
- Upping Shock Wave Frequency Improves Ureteral Stone Clearance
- Phosphate Binder Adherence Challenging for Dialysis Patients
- High Phosphorus Levels Predict CKD Progression, Early Death
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)